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Abstract
Background: An estimated 1.86 million people are living with HIV in Latin America and the Caribbean (LAC). The region is
comprised of mainly middle-income countries with steady economic growth while simultaneously there are enormous
social inequalities and several concentrated AIDS epidemics. This paper describes HIV spending patterns in LAC countries
including analysis of the levels and patterns of domestic HIV spending from both public and international sources.
Methods and Findings: We conducted an extensive analysis of the most recently available data from LAC countries using
the National AIDS Spending Assessment tool. The LAC countries spent a total of US$ 1.59 billion on HIV programs and
services during the latest reported year. Countries providing detailed information on spending showed that high
percentages are allocated to treatment and care (75.1%) and prevention (15.0%). Domestic sources accounted for 93.6
percent of overall spending and 79 percent of domestic funds were directed to treatment and care. International funds
represented 5.4 percent of total HIV funding in the region, but they supplied the majority of the effort to reach most-at-risk-
populations (MARPs). However, prevalence rates among men who have sex with men (MSM) still reached over 25 percent in
some countries.
Conclusions: Although countries in the region have increasingly sustained their response from domestic sources, still there
are future challenges: 1) The growing number of new HIV infections and more people-living-with-HIV (PLWH) eligible to
receive antiretroviral treatment (ART); 2) Increasing ART coverage along with high prices of antiretroviral drugs; and 3) The
funding for prevention activities among MARPs rely almost exclusively on external donors. These threats call for
strengthened actions by civil society and governments to protect and advance gains against HIV in LAC.
Citation: Ara ´n-Matero D, Amico P, Ara ´n-Fernandez C, Gobet B, Izazola-Licea JA, et al. (2011) Levels of Spending and Resource Allocation to HIV Programs and
Services in Latin America and the Caribbean. PLoS ONE 6(7): e22373. doi:10.1371/journal.pone.0022373
Editor: Abdisalan Mohamed Noor, Kenya Medical Research Institute - Wellcome Trust Research Programme, Kenya
Received February 9, 2011; Accepted June 23, 2011; Published July 22, 2011
Copyright:  2011 Ara ´n-Matero et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: avilac@unaids.org
Introduction
Though Latin America is regarded as a ‘low prevalence’ region,
the estimated 1.86 million people living with HIV will impose
significant challenges in the coming years for the provision of
health and social services [1,2]. The 0.6 percent prevalence among
HIV-infected adults in Latin America and the current stabilization
of infections does not reflect the growing epidemic that has been
unfolding over the last 30 years. Additionally, there has been a 22
percent increase in new infections between 2001 and 2009 which
points to strong preventive programs in the region [7]. In 2008,
Hotez et al. estimated that HIV accounts for 3.8 percent of the
burden of disease in LAC [8].
The Caribbean is the second hardest hit region in the world
with an infection rate of 1 percent and is a mix of generalized
(.1% prevalence) and concentrated epidemics [9]. HIV is equally
distributed between men and women, but higher prevalence is
found among young women [9]. The regional infections seems to
have stabilized with countries such as the Dominican Republic
and Haiti experiencing declines in HIV prevalence [9]. Surveys in
the region indicate high infection rates among sex workers ranging
from 9 to 27 percent [9,10]. Various studies of MSM infection
rates range from 20 to 31 percent in Jamaica and Trinidad and
Tobago respectively [9]. Though IDUs play a small role in the
epidemic in the Caribbean, it is the main mode of transmission in
Puerto Rico [9].
The Latin America and the Caribbean (LAC) regions are
exiting the economic crisis faster than expected due to solid
macroeconomic policy fundamentals, favorable external financ-
ing conditions and strong commodity revenues [11]. The
projected growth for the region is 5.7 percent in 2010 and 4
percent in 2011 [11]. As other emerging economies, the gap
between rich and poor is rising, situating LAC as the home to the
world’s most unequal societies; Brazil, Argentina and Chile all
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22373have GINI coefficients over 50 [12]. Social investment in Latin
America during the last 30 years have been directed to
transferring resources to the poor, creating temporary jobs and
investing in education and health in order to soften the effects of
the adjustment policies of the 1980s.
LAC has transitioned to more rapidly urbanized megacities
along with the rise of slums and extreme urban poverty within
these cities [13,14]. In fact, Mexico City, Sao Paulo, Buenos Aires
and Rio de Janeiro are all larger than 10 million people. More
than five million inhabitants populate five other cities: Bogota,
Lima, Santiago de Chile, Bello Horizonte and Guadalajara [13].
While, this allows more people to be in proximity of health
services, urbanization is also associated with the adoption of
unhealthy lifestyles—poor diet, obesity, lack of physical activity,
alcohol and drug use, risky sexual behavior, and increasing
violence and trauma [14]. Chronic non-communicable diseases
are also contributing substantially to overall mortality and disease
burden in the region [15].
National health expenditures in LAC represented approximate-
ly 6.8 percent of GDP or an annual per capita expenditure of US$
500 [14]. Domestic funding directed to health systems and HIV in
Latin America has been growing; in fact, there are 27,000 facilities
providing HIV testing services with more than 5 million people
tested in 2009. Anti-retroviral (ARV) coverage is widespread with
a reported 478,000 people receiving ART in LAC. On average,
ARV coverage has increased from 10 percent in 2004 to 50
percent in 2009 [7]. Though almost one million people need Anti-
retroviral treatment (ART); LAC pays ARV prices that are above
the global average [5].
The relatively low prevalence in Latin America is also diverting
the attention from the high prevalence concentrated epidemics
affecting specific groups [16]. The number of infections among
men is much higher than among women in the region; for
example, in Peru, the number of new male cases was three times
the number of female cases in 2008 [16]. Men who have sex with
men (MSM) have a one in three chance of being infected with
HIV in Latin America and account for the largest share of HIV
infections in the region [16]. Additionally, an estimated 29 percent
of IDUs in Latin America are infected with HIV, though these
infections are concentrated in the Southern Cone of South
America and along the Mexico US border [16,17]. The majority
of transmission in LAC is through unprotected sex including MSM
and both male, female and transgender sex workers, and there is
growing concern over the spread among injecting drug users
(IDUs) [1]. Cultural issues that have stigma, create dangerous
opportunities for HIV to continue unabated. In LAC countries
there is still a significant stigma associated with the disease which
has hampered efforts to achieve universal access to prevention,
treatment and care [18].
Monitoring the flow of resources for the HIV response provides
valuable strategic information that can improve operations and
planning, and mobilize greater resources. In regions where the
funding gap is increasing, the mapping of HIV expenditures
provides crucial guidance for the reallocation of resources and
supports evidence-based decision making. Funding information
also provides an indication of a country’s commitment to tackling
HIV, measured by domestic spending, and international support
for the HIV response, as measured through donor contributions.
Using the most recent available data, this paper describes HIV
spending in LAC countries. This includes analysis of the levels and
patterns of domestic HIV spending from public and international
sources and spending on most-at-risk populations, taking into
account country-income levels.
Methods
We conducted a descriptive analysis of HIV expenditures from
23 LAC countries using the most recently reported year—either
2008 or 2009. These countries included: Argentina, Belize,
Bolivia, Brazil, Chile, Colombia, Costa Rica, El Salvador,
Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, and
Venezuela. The Caribbean countries include Antigua and
Barbuda, the Bahamas, the Dominican Republic, El Salvador,
Grenada, Saint Kitts and Nevis, Saint Vincent and the
Grenadines, and Trinidad and Tobago. The available LAC data
consists of 23 countries—15 from Central and South America, 8
from the Caribbean.
We also conducted a trend analysis for those countries with
more than five reported points in time of domestic AIDS spending
in Latin America. These countries have conducted systematic and
standard resource tracking of AIDS spending since the mid 1990s
[6].
All expenditures on HIV were generated from reporting on the
United Nations General Assembly Special Session (UNGASS)
indicator number 1 and the National AIDS Spending Assessment
(NASA) tool which was developed by UNAIDS to measure all the
resources included in a country’s national HIV response and was
developed using the national health accounts framework [3,4].
These expenditures were cross- tabulated by source of financing
and stratified by income level. These reports are generated by
national resource tracking teams and do not include out-of-pocket
or other types of private spending.
NASA applies standard accounting methods to reconstruct all
transactions in a given country, following the money from the
funding sources to agents and providers, and eventually to
beneficiary populations. HIV spending is structured into eight
categories of spending: (1) prevention; (2) treatment and care; (3)
orphans and vulnerable children; (4) program management and
administration; (5) human resources; (6) social protection; (7)
enabling environment; and (8) research [19,20].
We also estimated the AIDS priority index, with the objective of
measuring a country’s ability to fund its own AIDS response and
the ability to sustain a long-term response. The index is estimated
by calculating each country’s percentage of government revenue
directed to the AIDS response divided by HIV prevalence [7]. A
high value usually indicates a high level of priority. If a country is
spending at least the average in relation to their resources and
HIV prevalence, it is giving a relatively high priority to AIDS.
Countries were classified by income level; economies were
divided according to their 2009 Gross National Income (GNI) per
capita, calculated using the World Bank Atlas Methods [21] and
grouped into four categories: low-income (US$ 975 or less); lower
middle-income (US$ 976–$3,855); upper middle-income (US$
3,856–$11,905); and high income (US$ 11,906 or more). There
are 9 lower middle-income countries (Belize, Bolivia, Colombia, El
Salvador, Guatemala, Honduras, Nicaragua, Paraguay, Peru), ten
upper-middle income countries (Argentina, Brazil, Chile, Costa
Rica, Dominican Republic, Grenada, Mexico, Panama, Saint
Vincent and the Grenadines and Venezuela), and four high
income countries (Antigua and Barbuda, the Bahamas, Trinidad
and Tobago, and St. Kitts and Nevis) [21,22]. Countries with no
reports from 2008–9 were excluded.
Results
The 23 LAC countries spent a total of US$ 1.59 billion on HIV
programs and services during the last reported year. Of those 23
countries, 20 provided detailed information on their levels of
spending within each of the eight different HIV spending
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largest share of funds (75.1%), with the remaining resources
divided between prevention (15.0%), program management and
administration strengthening (4.0%), creating an enabling envi-
ronment (2.0%), human resources (1.7%), research (.5%) and
orphans and vulnerable children (.1%).
Table 1, which lists the proportional allocation of international
and public resources for HIV, shows that international resources
are the dominant funding source for orphans and vulnerable
children (72%) followed by research (46%) and program
management (28%). Domestic resources are the primary funding
source of treatment and care (99%) followed by social protection
(99%) and prevention (83%). However, International funds are a
relatively minor part of HIV spending in many LAC countries and
overall account for 6% of the total funding (Table 2).
Most countries funded their own HIV response; domestic
sources accounted for 93.6 percent of overall spending. Domestic
spending ranged from 100 percent in Grenada to 8.4 percent in
Saint Vincent and the Grenadines. Notably, upper middle-income
countries such as: Venezuela, Colombia, Mexico, Chile and Brazil
funded more than 99 percent of their HIV response. However,
seven countries rely on external support to fund over half of their
response to HIV including: Nicaragua, Honduras, the Dominican
Republic, Bolivia, Belize, Dominica and Saint Vincent and the
Grenadines. External support made up 43 percent of the total
spending in the eight lower middle- income countries, 23 percent
in the 13 upper middle- income countries and 19 percent in the
three high- income countries.
The average growth rate for the two latest available years of
data was 12 percent. Of the countries observed, only four
experienced declines in the total spending for HIV: Grenada,
Mexico, Saint Kitts and Nevis and Trinidad and Tobago. All of
these countries cut their domestic spending on HIV between 2008
and 2009. Mexico also experienced a drop in international
funding during the last year reported while the other countries
continued to receive additional international support. Internation-
al funding grew at an average rate of 34 percent with only Mexico,
Peru and Venezuela experiencing declines. Brazil and Argentina
showed the largest expansion of funds in absolute terms, with
resource levels increasing by US$ 47.9 million and US$ 39.3
million respectively between 2007 and 2008. For those countries
whose funding increased, they ranged from 3 percent in El
Salvador to 62 percent in Saint Vincent and the Grenadines.
Spending patterns varied across all countries, as reflected in
Table 2, which shows total and per capita spending, and the
proportion of international contributions. Brazil (US$ 623.1
million) is the largest spender in absolute terms, trailed by
Argentina (US$ 248.7 million) and Mexico (US$ 218.4 million).
Saint Vincent and the Grenadines is the biggest per capita spender
at US$ 42.22 per capita. Annually, countries spent US$ 9.14 per
capita on HIV and US$ 1,156 per person living with HIV
(PLWH), however, this was mostly driven by the high spending in
countries with low numbers of PLWH which have higher fixed
costs.
Although treatment and care received 73 percent of total
resources, Belize, Bolivia, and Honduras allocated a greater
proportion of resources to prevention than treatment and care,
allocating 27, 37 and 59 percent respectively. The highest
proportion of spending on treatment and care occurred in
Venezuela with 88 percent of the funds going to treatment and
care. Several countries spent a very high percentage of their
spending on program management and administration. The
Bahamas, the Dominican Republic, Belize, and St. Kitts and
Nevis spent 22.8, 39, 40 and 83 percent respectively. This was
primarily driven by external support in Belize, Bolivia and the
Dominican Republic. However, in the highest spender, St. Kitts
and Nevis, domestic funding drove this large share.
The most at risk populations (MARPs) in the HIV epidemic in
LAC include sex workers and their clients, men who have sex with
men (MSM) and injecting drug users (IDUs). Colombia, Mexico,
Venezuela and Chile are the only countries who domestically fund
outreach to MARPs and these funds are only 1, 3, 5 and 12
percent of overall prevention spending respectively. The remain-
ing countries have either no funding for MARPs or are completely
reliant on external donors. Peru has the highest percentage of
prevention spending targeted at MARPs with 36 percent while 9
of the 20 countries with detailed reporting have no funding
targeted at MARPs. As seen in Figure 1, the proportion of
preventive spending allocated towards MSM is relatively low in
most countries, especially in comparison to HIV prevalence rates
among MSM.
Anti retroviral treatment (ART) is an important component of
domestic HIV funding in LAC. Most of the funding to support ART
Table 1. Reported total, international and domestic spending on HIV spending categories in 20 LAC countries (latest year
available).
HIV Spending Categories Total Spending
Percent of
Spending Total Public Spending Total Int’l Spending
Percent
International
1. Prevention $ 237,745,926 15.0% $ 193,134,352 $ 39,943.029 17%
2. Care and Treatment $ 1,190,983,632 75.1% $ 1,171,664,929 $ 17,057,633 1%
3. Orphans and Vulnerable Children $ 2,126,125 0.1% $ 561,244 $1,535,738 72%
4. Program Management and
Administration Strengthening
$ 63,742,356 4.0% $ 43,686,487 $17,627,592 28%
5. Human resources $ 27,330,314 1.7% $ 19,662,261 $2,949,854 11%
6. Social Protection and Social Services
excluding Orphans and Vulnerable
Children
$ 22,939,222 1.4% $ 22,607,171 $ 332,051 1%
7. Enabling Environment $ 32,019,116 2.0% $ 23,766,462 $7,715,162 24%
8. Research $ 8,644,643 0.5% $ 4,359,132 $3,935,298 46%
TOTAL $ 1,585,531,333 - $ 1,479,442,039 $ 91,096,357 -
doi:10.1371/journal.pone.0022373.t001
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domestic funding for HIV. The only country that primarily relied on
donor support for ART was Paraguay, who received 71 percent of
their funding from external sources. However, the remaining
countries funded 85 percent or more of their ART response with
many countries funding 100 percent of the effort. The average LAC
country spent 47 percent of their care and treatment budget on ART,
ranging from 9 percent in the Bahamas to 93 percent in Chile.
Figure 2 shows 9 countries’ total spending on care and
treatment divided by the number of people on ART in the
country. On average, ART was responsible for half of the care and
treatment budget. Therefore, these do not represent the unit costs
of ART, but rather the cost per person on treatment and care
including drug and non-drugs costs. There is wide variation in the
average cost of treatment ranging from US$ 843 in Peru to US$
3,128 in Mexico.
Table 2. Reported total and per capita per year spending and proportion of international funding in 20 LAC countries (latest year
available).
Country Year
Income
Level
% International
Funding
Total HIV
Spending
HIV Spending per
Capita
Epidemic
State PLWHIV
HIV Spending
per PLWHIV
Grenada 2009 Upper
middle
0% $ 194,493 $ 2.62 L 403 $ 483
Venezuela 2009 Upper
middle
0% $ 78,800,637 $ 2.89 C 136,625 $ 577
Colombia 2009 Lower
middle
1% $ 108,791,907 $ 4.03 C 173,911 $ 626
Mexico 2009 Upper
middle
1% $ 218,421,242 $ 3.35 C 215,563 $ 1,013
Chile 2008 Upper
middle
1% $ 88,012,301 $ 7.34 C 31,811 $ 2,767
Brazil 2008 Upper
middle
1% $ 623,133,515 $ 3.82 C 391,257 $ 1,593
Argentina 2008 Upper
middle
3% $ 248,772,695 $ 10.82 C 122,074 $ 2,038
Costa Rica 2008 Upper
middle
7% $ 19,884,919 $ 7.28 C 9,953 $ 1,998
Bahamas 2009 High
income
10% $ 4,888,516 $ 16.30 G 6,477 $ 755
Saint Kitts and Nevis 2009 Upper
middle
11% $ 1,210,091 $ 29.67 C 314 $ 3,854
Panama 2008 Upper
middle
13% $ 13,627,719 $ 7.24 C 20,351 $ 670
Trinidad and Tobago 2009 High
income
16% $ 13,532,974 $ 15.69 C 13,962 $ 969
El Salvador 2008 Lower
middle
20% $ 39,227,433 $ 11.98 C 35,975 $ 1,090
Paraguay 2009 Lower
middle
32% $ 11,417,737 $ 3.31 C 22,118 $ 516
Antigua and Barbuda 2009 High
income
34% $ 390,760 $ 6.64 C 815 $ 479
Peru 2009 Lower
middle
45% $ 43,638,623 $ 2.88 C 80,281 $ 544
Nicaragua 2008 Lower
middle
58% $ 14,908,986 $ 5.95 C 7,866 $ 1,895
Honduras 2008 Lower
middle
62% $ 24,319,656 $ 6.44 C 28,803 $ 844
Dominican Republic 2008 Lower
middle
65% $ 23,415,929 $ 3.95 C 62,009 $ 378
Belize 2009 Upper
middle
68% $ 2,024,335 $ 9.68 C 3,957 $ 512
Dominica 2009 Upper
middle
83% $ 177,655 $ 4.22 C 350 $ 508
Bolivia 2009 Lower
middle
87% $ 7,418,172 $ 1.83 L 8,562 $ 866
Saint Vincent/Grenadines 2009 Upper
middle
92% $ 2,629,219 $ 42.22 C 427 $ 6,157
Total 6% $ 1,588,839,511 $ 9.14 1,373,864 $ 1,156
doi:10.1371/journal.pone.0022373.t002
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that, in 16 LAC countries, there was a nearly 60 percent increase
in AIDS financing between 1999 and 2009, equivalent to an
annual growth of 6%. In 2008, overall funding essentially
remained flat, growing by less than 0.5 percent. Domestic funding
accounts for the majority of funding in the region and
international support is mostly targeted at low-income countries.
As illustrated in Figure 4, the domestic priority HIV index
shows a country’s ability to fund its own AIDS response. The
median domestic priority-spending index of 0.68 as estimated for
19 countries in the region; ten countries are spending above the
average in the region in relation to their resources and HIV
prevalence, thus giving relatively high priority to AIDS.
Spending in eight countries, Argentina, El Salvador, Mexico,
Brazil, Chile, Honduras, Panama and Nicaragua, exhibit a
relatively high degree of priority given to HIV. On the contrary,
Paraguay, Barbados, Colombia, Uruguay, Peru, Bolivia, Vene-
zuela, the Dominican Republic, Belize, and Trinidad spend less
than average in relation to their resources and HIV prevalence.
These countries seem to have the potential to increase their
domestic spending.
Discussion
While this region accounts for 5% of the global number of
people living with HIV [7,23], the estimated US$ 1.59 billion
spent in the 23 countries analyzed here represents 10 percent of
the US$ 15.9 billion available for HIV in low- and middle-income
countries in 2009 [7]. The US$ 1.59 billion spent in the region falls
below the US$ 3.1 billion needed to achieve HIV universal access
targets in Latin America and the Caribbean by 2010 [7,24]. Also,
the average LAC country spent 1.1 percent of their overall health
budget on HIV related activities [25].
Resources for HIV have generally been on the rise in the region
in recent years. According to internally collected NASA data,
spending has grown at an annual rate of 6 percent in 16 countries
reporting data for 10 years with few experiencing declining growth
rates of HIV resources. The epidemic is stable or decreasing in all
of the LAC countries which provides an opportunity to scale up
HIV funding to meet funding needs [7]. Brazil and Argentina
showed the largest increases in funding while Cuba and Saint
Vincent and the Grenadines had the largest percentage growth.
This is an encouraging trend, especially in the presence of a
stabilizing or declining epidemic and steady regional economic
growth.
Treatment represents 79% of public spending on AIDS in LAC
and about half of this amount is invested in antiretroviral drugs.
An additional burden comes from the fact that ART prices are
above the global average in LAC [5]. Veronika Wirtz, et al.
proposed that this is largely due to procurement methods and
donor policies. As LAC has not been the focus of major price-
reducing efforts in the same way as Sub-Saharan Africa, the prices
Figure 1. Prevalence among MSM and Spending on MSM as a Percent of Preventive Spending.
doi:10.1371/journal.pone.0022373.g001
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scale-up efforts and to the future sustainability of HIV treatment
[26]. The LAC countries could increase their market power by
purchasing as one unit, creating a regional purchasing entity and
incorporating generics [27].
The LAC region has not benefited from reductions in the
prices of first-line regimens; the weighted median price of the six
most widely used first-line regimens was US$ 137 per person per
year in low-income countries. However, in LAC, the cost of first-
line regimens is comparable to the US$ 202 paid by middle-
income countries and to the US$ 1,378 paid for second line
regimens. In the Americas Region, at least 10 percent of patients
are being treated with a second-line regimen and an additional
six percent are on salvage therapy. This is most likely due to the
relatively longer duration and maturity of antiretroviral therapy
programs in LAC’s largest countries [28]. This may also help to
explain the relatively higher costs of ART programs in LAC
[29].
Since the largest source of HIV funding in LAC is domestic
expenditure; the domestic priority HIV index shows a country’s
ability to fund its own AIDS response. More than half of the
countries are spending above the average in the region in relation
to their income and HIV prevalence, thus giving relatively high
priority to AIDS. It is also possibly that this is a result of higher
unit costs, especially for ARVs. The other half of countries would
seem to have potential to increase their domestic spending
sustainably. Colombia and Venezuela, two countries in South
America with relatively high HIV prevalence, are spending at
relatively low levels given their disease burden and ability to pay;
thereby they could contribute more to the AIDS response from
domestic resources.
Although domestic funding was the largest overall source of
funding, due mainly to high domestic funding levels in Argentina,
Brazil, Colombia and Mexico; over 40 percent of the countries
receive more than one-third of their funding from international
sources. In fact, seven countries receive more than half of their
funding from non-domestic sources. External funding is particu-
larly high for MARPs, where it accounts for almost all
expenditures. It is worth noting that only a limited number of
donor governments and philanthropic organizations invest in
harm reduction approaches, raising the possibility that these
approaches could be left even more underfunded if resources from
international donors are reduced. The Global Fund is not a major
player in the region as it has provided small grants to a few
countries, most recently Mexico [30]. However, they have the
potential to become an important resource in the region, especially
if they support marginalized populations that are left behind by
public programs.
Expenditures for prevention are low and represent only 15% of
total spending in the region, especially under-funded are programs
to prevent the expansion of concentrated epidemics and targeting
MARPs—only 4 percent of total spending for prevention. In fact,
this 4 percent of spending is almost fully from external donors
rather than domestic funding sources. Although it is widely
acknowledged that a significant portion of the transmission in
LAC is through MSM, Sex workers and in some regions, IDUs;
LAC countries are unwilling to fund prevention programs targeted
at these MARPs. Some countries, such as Mexico have recently
implemented harm reduction programs for high-risk populations
[31].
Despite the fact that the HIV epidemic in LAC is driven by
MARPs, especially MSM and sex workers, the majority of
Figure 2. Treatment and Care Spending Per Person on ART in 9 LAC Countries in 2008.
doi:10.1371/journal.pone.0022373.g002
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funding mismatch points to a critical decision to reallocate scarce
funding resources to where they can be most effective. In LAC
countries, there is still a pervasive belief that HIV is a moral
infection, thus governments are hesitant to fund targeted
prevention efforts due to the stigma associated with these MARPs
[18]. In order to continue making progress against the HIV
epidemic more resources must be strategically focused on MARPs.
Failure to address the role of MSM and sex workers in HIV
transmission could have serious health outcomes in the region. A
study by Aldridge et al., found that cost-effectiveness of
interventions among these groups ranged from US$ 55 to 5,928
per DALY averted in Peru [32]. Surveys in the region indicate
infection rates ranging from 9 to 27 percent [9,16]. Additionally,
along the US-Mexico border and the southern cone of South
America there is a high HIV infection rate among IDUs, 29
percent, which is of growing concern [16]. The data produced for
this analysis clearly show that many LAC countries are not
allocating their HIV resources in ways that are likely to achieve the
greatest possible impact, particularly with respect to injecting drug
users and other MARPs. Despite the significant political hurdles in
addressing MARPs, strategic and evidence-based allocation of
resources is even more critical during the global economic
downturn, when it is probable that both national budgets and
international contributions will remain flat or decrease.
The economic crisis has created widespread concerns that
funding shortages will have an impact on prevention programs
that work with stigmatized and marginalized population groups.
LAC has emerged from the crisis relatively unscathed and has
returned to positive growth [11]. It is expected that condom
distribution and programs for IDUs could be seriously affected due
to cost constraints and the immediacy of ART taking priority.
However, the consequences of ignoring preventive programs will
have a long-term impact in the LAC countries. The region also
may expect negative impacts on national ART efforts and a
decrease in financial resources for ART over the next year. A
substantial contraction in the regional economy, plus devaluations
of local currencies, could force some governments to cut overall
public spending affecting the resources of national health
insurance funds, which in some countries cover AIDS treatment
costs.
The LAC countries have a long history of social security;
coverage generally reflects the proportion of those workers who
are employed in the formal sector—30–60 percent with the
exception of some Caribbean islands where the formal economy is
bigger [33]. It is estimated that approximately 140 million people
do not have health insurance in LAC [34]. The uninsured
population is at risk of catastrophic health expenditures, high out-
of-pocket expenditures on health and the under-utilization of
necessary health services [35,36]. On average, households pay
about one quarter of the total financial burden of HIV/AIDS
expenses in LAC [37]. Households in Peru, Honduras, Paraguay,
Uruguay and Belize take a share or more than one third of HIV/
AIDS expenses; Peru is by far the largest with a share of nearly 80
Figure 3. Public HIV Spending in 16 LAC Countries 1999–2009.
doi:10.1371/journal.pone.0022373.g003
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and Venezuela have low shares of out-of-pocket spending on
HIV—less than 15 percent [37]. The sustainability of the domestic
response to HIV is in question if a high number of people are
expected to pay out-of-pocket expenses for treatment.
This study is based on secondary analysis and has some
limitations, as country reports may be incomplete and subject to
variable levels of measurement error. Expenditures are estimated
from different sources of information and some countries lack
comprehensive and regular expenditure records and accounting
information systems. The variation of NASA measurements across
countries may limit the accuracy of the data. However, monitoring
and evaluation officers in the region have improved the
substantive basis for estimates of financial resources, while also
working closely with countries to generate reliable data through
the NASA resource tracking methodology [38]. Our analysis is
limited to external and government sources of funding, neither of
which include out-of-pocket or other private forms of household
and business spending. Additionally, this analysis was only able to
analyze total expenditures for 23 of the 26 LAC countries and
detailed expenditures for 20 of the 26 LAC countries, thus our
figures are slightly conservative for the region. This is not seen as a
major limitation because the largest economies were all included.
The top spender in the LAC region, Brazil is also an upper-
middle income country and is one of the four emerging key
emerging economies referred to as BRICs (Brazil, Russia, India
and China) with solid economic growth and an increasing share of
the global gross domestic product. Brazil was the first middle-
income country worldwide to guarantee universal access at no cost
at the point of delivery of ARV treatment [2]. Brazil has also
developed a generic drug industry and has been negotiating for
greater use of the flexibilities regarding public health within the
Trade-Related Intellectual Property Rights Agreement [39]. Brazil
also has been engaged with the Global Fund; however, its
disbursements of US$ 36 million are specifically for tuberculosis
and malaria [40,41,42]. If Brazil ceases to be a recipient of
international aid and shifts their support to less developed
countries, then Brazil can play a major role and contribute to
the global health policy agenda in LAC.
There are several threats to future sustainability in the current
AIDS response: 1) an increasing number of new HIV infections
along with more people-living-with-HIV reaching eligibility to
receive ART, 2) an increasing coverage of ART, responsible for a
large share of spending in LAC, and high prices paid for first and
second line ARVs, 3) low income countries in the region receive
more than one-third of their funding from international sources,
and 4) prevention activities for MARPs are not only domestically
under-funded, but also heavily reliant on external support.
Priority attention for the national responses in LAC should be
given to ensuring treatment and care is included in social
insurance schemes as well as an intensified focus on prevention.
Also, strategic campaigns should be launched with the goal of
Figure 4. AIDS Priority Index by Country.
doi:10.1371/journal.pone.0022373.g004
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ing to induce demand of preventive services. Governments should
also develop strategies to move toward financial sustainability of
AIDS programs while simultaneously increasing transparency and
accountability. These objectives can only succeed with an engaged
civil society and government partnerships to protect and advance
gains against HIV in LAC.
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